 |
|
UF makes gene therapy advance in severe genetic disorder
May 29, 2009GAINESVILLE - A dog born with a deadly disease that prevents the body from using stored sugar has survived 20 months and is still healthy after receiving gene therapy at the University of Florida - putting scientists a step closer to finding a cure for the disorder in children.
Called glycogen storage disease type 1A, the genetic disease stops the body from being able to correctly store and use sugar between meals. In order to survive, children and adults with this disease must receive precise doses of cornstarch every few hours. The disease is even more dire in dogs, which must be fed sugar every 30 minutes to survive.
"Without treatment, these dogs all die," said David Weinstein, M.D., M.M.Sc., director of the UF Glycogen Storage Disease Program and co-investigator on the study. "People usually survive because they are fed so much as infants. But by 4 to 6 months of age, they will have developmental delays and a big liver. If it is diagnosed at that point, the kids can do fine. If it is not diagnosed, then the kids get exposed to recurrent low sugars, and they will end up with brain damage, seizures or they will die."
UF researcher Cathryn Mah, Ph.D., a member of the Powell Gene Therapy Center and UF Genetics Institute, will present the findings at an American Society of Gene Therapy meeting this weekend in San Diego.
About one in 100,000 children have this severe form of glycogen storage disease. Children receive doses of cornstarch at scheduled intervals throughout the day because it metabolizes more slowly than other carbohydrates. Until this therapy was discovered about 30 years ago, most children born with this disease did not survive past infancy.
Glycogen storage disease type 1A stems from a faulty enzyme that doesn't convert stored sugar, or glycogen, to glucose, the type of sugar the body uses for energy. This prevents the body from getting the energy it needs and causes glycogen to build up in the liver.
The goal of gene therapy is to restore the faulty enzyme so the body uses sugar properly, said Mah, a UF assistant professor of pediatric cellular and molecular therapy and a co-investigator on the study.
The dog, which comes from a line of dogs genetically prone to the disease, received its first dose of gene therapy the day after it was born, Mah said. The dog improved at first, often going as long as two to three hours without needing additional glucose to supplement its diet. But several weeks later the progress stopped.
When the dog was 5 months old, the researchers administered another dose of gene therapy, this time using a different type of AAV. Six weeks after the therapy, the dog was completely weaned off glucose supplements.
"We have never had to use any glucose supplementation since we weaned her off," Mah said. "She just gets fed normal dog food. That is a huge improvement in quality of life."
A few years ago, when Weinstein, Mah and other UF and National Institutes of Health collaborators began discussing the project, the longest a dog with the disease had lived was 28 days. The dog treated at UF is now 20 months old.
"The success is beyond what I would have imagined at this stage," Weinstein said. "To have a dog off treatment for 14 months that is clinically doing great with outstanding lab results is beyond what I even dreamt about."
Researchers hope to eventually establish a clinical trial in humans, but for now would like to test gene therapy in dogs again within the next year, Weinstein said.
"This is very exciting work and holds great promise for treatment of the disease in humans," said Joseph Wolfsdorf, M.B., B.Ch., a pediatric endocrinologist at Children's Hospital Boston and professor of pediatrics at Harvard Medical School who studies glycogen storage disease in children.
Finding better treatments for the glycogen storage disease is crucial because the disorder is still associated with multiple complications, and care remains a challenge. As a result of the lack of expertise in this condition, children and adults also must travel to special centers for care. With more than 300 patients from 18 countries, UF's Glycogen Storage Disease Program is the largest in the world.
University of Florida
UF researcher Cathryn Mah, Ph.D., a member of the Powell Gene Therapy Center and UF Genetics Institute, will present the findings at an American Society of Gene Therapy meeting this weekend in San Diego.
About one in 100,000 children have this severe form of glycogen storage disease. Children receive doses of cornstarch at scheduled intervals throughout the day because it metabolizes more slowly than other carbohydrates. Until this therapy was discovered about 30 years ago, most children born with this disease did not survive past infancy.
Glycogen storage disease type 1A stems from a faulty enzyme that doesn't convert stored sugar, or glycogen, to glucose, the type of sugar the body uses for energy. This prevents the body from getting the energy it needs and causes glycogen to build up in the liver.
The goal of gene therapy is to restore the faulty enzyme so the body uses sugar properly, said Mah, a UF assistant professor of pediatric cellular and molecular therapy and a co-investigator on the study.
The dog, which comes from a line of dogs genetically prone to the disease, received its first dose of gene therapy the day after it was born, Mah said. The dog improved at first, often going as long as two to three hours without needing additional glucose to supplement its diet. But several weeks later the progress stopped.
When the dog was 5 months old, the researchers administered another dose of gene therapy, this time using a different type of AAV. Six weeks after the therapy, the dog was completely weaned off glucose supplements.
"We have never had to use any glucose supplementation since we weaned her off," Mah said. "She just gets fed normal dog food. That is a huge improvement in quality of life."
A few years ago, when Weinstein, Mah and other UF and National Institutes of Health collaborators began discussing the project, the longest a dog with the disease had lived was 28 days. The dog treated at UF is now 20 months old.
"The success is beyond what I would have imagined at this stage," Weinstein said. "To have a dog off treatment for 14 months that is clinically doing great with outstanding lab results is beyond what I even dreamt about."
Researchers hope to eventually establish a clinical trial in humans, but for now would like to test gene therapy in dogs again within the next year, Weinstein said.
"This is very exciting work and holds great promise for treatment of the disease in humans," said Joseph Wolfsdorf, M.B., B.Ch., a pediatric endocrinologist at Children's Hospital Boston and professor of pediatrics at Harvard Medical School who studies glycogen storage disease in children.
Finding better treatments for the glycogen storage disease is crucial because the disorder is still associated with multiple complications, and care remains a challenge. As a result of the lack of expertise in this condition, children and adults also must travel to special centers for care. With more than 300 patients from 18 countries, UF's Glycogen Storage Disease Program is the largest in the world.
University of Florida
Gene Therapy Current Events and Gene Therapy News RSSImmune therapy can protect against or treat later lymphoma
Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection.
Caltech researchers show efficacy of gene therapy in mouse models of Huntington's disease
Researchers at the California Institute of Technology (Caltech) have shown that a highly specific intrabody (an antibody fragment that works against a target inside a cell) is capable of stalling the development of Huntington's disease in a variety of mouse models.
Immunotherapy demonstrates long-term success in treating lymphoma
Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).
Toward bold new anti-cancer medicines
Bold new strategies in the battle against cancer may turn forms of the disease that presently are incurable into manageable conditions that can be controlled for long periods of time.
1 shot of gene therapy and children with congenital blindness can now see
Born with a retinal disease that made him legally blind, and would eventually leave him totally sightless, the nine-year-old boy used to sit in the back of the classroom, relying on the large print on an electronic screen and assisted by teacher aides.
Master regulator found for regenerating nerve fibers in live animals
Researchers at Children's Hospital Boston report that an enzyme known as Mst3b, previously identified in their lab, is essential for regenerating damaged axons (nerve fibers) in a live animal model, in both the peripheral and central nervous systems.
Governor recognizes stem cell research at Einstein
Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today.
Michigan hospital launches gene therapy study for Parkinson's disease
A Michigan hospital is embarking on a research study for advanced Parkinson's disease using a state-of-the-art treatment called gene transfer.
Historic gene therapy trial to treat Alzheimer's disease underway at Georgetown
Researchers in the Memory Disorders Program at Georgetown University Medical Center are now recruiting volunteers for a national gene therapy trial - the first study of its kind for the treatment of patients with dementia due to Alzheimer's disease.
University of Iowa scientists use blood-brain barrier as therapy delivery system
The blood brain barrier is generally considered an obstacle to delivering therapies from the bloodstream to the brain. However, University of Iowa researchers have discovered a way to turn the blood vessels surrounding brain cells into a production and delivery system for getting therapeutic molecules directly into brain cells.
More Gene Therapy Current Events and Gene Therapy News Articles
 |
Gene Therapy: Treating Disease by Repairing Genes (New Biology) by Joseph, Ph.D. Panno (Author) Many diseases are caused by a simple point mutation - they are the result of a single defective gene. Gene therapy is the attempt to replace a defective gene with a good copy or to add a good gene to compensate for the bad. Although this procedure has proven to be extremely hazardous, of all the technologies provided by the new biology, gene therapy holds much potential for curing disease. Dealing with one of the most controversial aspects of the new biology, Gene Therapy explores the development and future of this area of research and explains why it is considered such a promising branch of science. This encyclopedia presents an overview of genetic defects, viruses, and gene therapy in a way that students and general readers will find easy to understand. Comprehensive in scope, this book... |
 |
Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Third Edition by Nancy Smyth Templeton (Editor) Since the publication of the second edition of this book in 2004, gene therapy and cell therapy clinical trials have yielded some remarkable successes and some disappointing failures. Now in its third edition, Gene and Cell Therapy: Therapeutic Mechanisms and Strategies assembles many of the new technical advances in gene delivery, clinical applications, and new approaches to the regulation and modification of gene expression. New Topics Covered in this Edition: Gene and Cell Therapies for Diabetes and Cardiovascular Diseases Clinical Trials Human Embryonic Stem Cells Tissue Engineering Combined with Cell Therapies Novel Polymers Relevant Nanotechnologies SiRNA Therapeutic Strategies Dendrimer Technologies Comprised of... |
 |
Gene Therapy by Mary Colavito (Author), Michael A. Palladino (Author) KEY MESSSAGE: Will gene therapy one day become the ultimate application of genetic technology? Gene Therapy, the newest booklet in the Special Topics in Biology Series, addresses this question by exploring gene therapy as a complex technology for delivering therapeutic genes as a way to treat and cure human genetic diseases. Author Mary Colavito provides an overview of the basic science involved in gene therapy methods and chronicles the history of gene therapy by discussing successful and ongoing gene therapy treatments as well as adverse outcomes in some cases of gene therapy. Also discussed are challenges that must be overcome for gene therapy to become a more reliable and readily accessible approach for treating a multitude of genetic diseases that affect... |
 |
Gene Therapy: Dawn of a New Age in Medicine (NCME Video 653) Also With: Kenneth W. Culver (Primary Contributor), Network For Continuing Medical Education (Primary Contributor) |
|
Gene Therapy & Molecular Biology by Intl Soc Gene Therapy Mole Bio | |
 |
Gene Therapy and Gene Delivery Systems (Advances in Biochemical Engineering / Biotechnology) by David V. Schaffer (Editor), Weichang Zhou (Editor) 1 D.V. Schaffer, W. Zhou: Gene Therapy as Future Human Therapeutics.- 2 J. Heidel, S. Mishra, M.E. Davis: Molecular Conjugates.- 3 M. Manthorpe, P. Hobart, G. Hermanson, M. Ferrari, A. Geall, B. Goff, A. Rolland: Plasmid Vaccines and Therapeutics: From Design to Applications.- 4 S.R. Little, R. Langer: Non-Viral Delivery of Cancer Genetic Vaccines.- 5 J.C. Grieger, R.J. Samulski: Adeno-Associated Virus as a Gene Therapy Vector: Vector Development, Production and Clinical Applications.- 6 J.H. Yu, D.V. Schaffer: Advanced Targeting Strategies for Murine Retroviral and Adeno-Associated Viral Vectors.- 7 N. Loewen, E.M. Poeschla: Lentiviral Vectors.- 8 N.E. Altaras, J.G. Aunins, R.K. Evans, A. Kamen, J.O. Konz, J.J. Wolf: Production and Formulation of Adenovirus Vectors.- |
 |
Charlie Rose (August 30, 2000) A rebroadcast of an interview that originally aired on June 21, 2000. Part three of the special edition series, "Mapping the Human Genome." First, three prominent scientists on how the decoding of the genome will lead to breakthroughs in the battle against disease. They are Dr. Harold Varmus, president of Memorial Sloan-Kettering Cancer Center, Dr. Arnold Levine, president of Rockefeller University, and Dr. Savio Woo, president of the American Society of Gene Therapy.||Then, Dr. James Watson, Nobel laureate, co-discoverer of the double-helix structure of DNA and president of Cold Springs Harbor Laboratory, discusses public and private genome projects and his new book, a collection of his essays over the years called A Passion for DNA. This product is manufactured on demand using DVD-R... |
 |
Jazz Therapy, Vol. 1: Smile by Gene Bertoncini & Roni Ben-Hur The first in a new series of fundraising CDs produced in association with the Jazz Foundation of America, and the first time these two popular guitarists have recorded together. Liner notes by Ira Gitler. Entire CD was played, recorded, packaged, and is being promoted on a pro-bono basis, raising funds for the Englewood Hospital and Medical Center's Dizzy Gillespie Fund. |
 |
Chromosome 11 Gene Therapy Sickle Cell Anemia Photographic Poster Print, 24x32 by Art.com Art.com is the world's largest retailer of art prints, posters, photographs, and framed artwork. With our huge selection of over 400,000 prints, you'll easily find the perfect piece for your home, office, or classroom. Our art is printed on quality paper. When you order framed artwork, the piece is built by our team of in-house professionals. Visit our Amazon store today at www.amazon.com/artdotcom to find Special Offers and search for products based on 'Artist Name' and 'Subject Categories' such as Movie, Music, Vintage, TV, Children, Travel, Kitchen, Museum Art, Animals, Floral, Motivational, and Sports. Art.com is dedicated to providing you with high quality products and service by offering you 100% satisfaction guaranteed. We ship internationally to over 80 countries. Decorate your... |
 |
Sexual Therapy (Watch ya Step Mix) Gene Farris (Primary Contributor) |
| © 2009 BrightSurf.com |